GPC2 MAY BE AN IMMUNOTHERAPEUTIC TARGET IN HIGH-RISK NEUROBLASTOMA
AMER ASSOC CANCER RESEARCH
September 22, 2017
Bosse, KR, P Raman, Z Zhu, M Lane, D Martinez, and S Heitzeneder. 2017. "GPC2 MAY BE AN IMMUNOTHERAPEUTIC TARGET IN HIGH-RISK NEUROBLASTOMA." In.: AMER ASSOC CANCER RESEARCH 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA.
